WO2023285347 - NOVEL FATTY ACID MODIFIED UROCORTIN 2 DERIVATIVES AND THE USES THEREOF
National phase entry is expected:
Publication Number
WO/2023/285347
Publication Date
19.01.2023
International Application No.
PCT/EP2022/069248
International Filing Date
11.07.2022
Title **
[English]
NOVEL FATTY ACID MODIFIED UROCORTIN 2 DERIVATIVES AND THE USES THEREOF
[French]
NOUVEAUX DÉRIVÉS D'UROCORTINE 2 MODIFIÉS PAR UN ACIDE GRAS ET LEURS UTILISATIONS
Applicants **
NOVO NORDISK A/S
Inventors
LI, Chien
COX, Nicholas Raymond
O'NEILL, Jason
GARIBAY, Patrick William
CHRISTOFFERSEN, Berit Østergaard
ÅSBERG, Hans Dennis
LYKKE, Lennart
ROED, Nikolaj Kulahin
Priority Data
63/220,788
12.07.2021
US
21201010.2
05.10.2021
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2242 | |
| EPO | Filing, Examination, Granting | 8875 | |
| Japan | Filing, Examination, Granting | 2199 | |
| South Korea | Filing, Examination, Granting | 2065 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
20,121
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Ucn2 derivatives comprising a peptide and a substituent with high potency, high physical and high chemical stability, suitable for administration to humans, and their medical use in treatment and/or prevention of obesity and/or diabetes.[French]
L'invention concerne des dérivés de Ucn2 comprenant un peptide et un substituant ayant une puissance élevée, une stabilité physique élevée et une stabilité chimique élevée, appropriés pour une administration à des êtres humains, et leur utilisation médicale dans le traitement et/ou la prévention de l'obésité et/ou du diabète.